Christian Dunne, Head of Sterile Solutions, ChargePoint Technology07.02.20
The global contract manufacturing organization (CMO) market is growing at a compound annual growth (CAGR) of 12–13 percent between 2018 and 2022. The growth is attributed to increased outsourcing of generic drugs by Big Pharma companies. Additionally, medium and small pharma and biopharma companies, who do not possess adequate infrastructure, will also outsource, thereby driving the market. Presently, non-sterile drug manufacturing dominates the global CMO market. However, the sterile manufacturing market is expected to grow at a higher rate (15 percent) than the non-sterile market (9 percent) thru 2022.
Manufacturing environments
As sterile drug products are on the rise, manufacturing environments are challenged to ensure that suitable control measures are put in place to mitigate many sources of potential contamination. These include operators, equipment and other materials present in the manufacturing environment. Should microorganisms, particles or endotoxins enter the manufacturing environment, patient safety could be put at risk.
Several technologies have been developed over the
Manufacturing environments
As sterile drug products are on the rise, manufacturing environments are challenged to ensure that suitable control measures are put in place to mitigate many sources of potential contamination. These include operators, equipment and other materials present in the manufacturing environment. Should microorganisms, particles or endotoxins enter the manufacturing environment, patient safety could be put at risk.
Several technologies have been developed over the
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
